Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
05 févr. 2015 06h15 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - February 05, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFED® Sinus Pressure +...
Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
08 janv. 2015 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - January 08, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the...
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
23 déc. 2014 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - December 23, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine...
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
08 déc. 2014 06h30 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, ILL--(Marketwired - December 08, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has...
Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results
03 nov. 2014 16h30 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - November 03, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse,...
Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
28 oct. 2014 11h11 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - October 28, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company...
Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development
16 oct. 2014 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - October 16, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's...
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints
29 sept. 2014 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Sep 29, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION®...
Acura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone Bitartrate With Acetaminophen Tablets
15 sept. 2014 06h00 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Sep 15, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert®,...
Acura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology
27 août 2014 06h15 HE
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - Aug 27, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug...